A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 93 (1), 229-232
- https://doi.org/10.1016/j.ygyno.2003.12.037
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Chemotherapy for recurrent ovarian cancerThe Lancet, 2003
- Part II: Chemotherapy for epithelial ovarian cancer-treatment of rcurrent diseaseThe Lancet Oncology, 2002
- Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic ToxicityJournal of Clinical Oncology, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 1999
- Salvage therapy for ovarian cancer.Current Oncology Reports, 1999
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997